Biotech Values

[semi_infinite]

Couple of thousand for the type of patients that MDACC treated. Ironic in what the LuminIce drop outs for cohort 1 and 2 show is that patients and docs don't what to fool around with failing everything before going to AFM13 after failing chemo and CPI. So that implies a bigger market. Still to begin is the cd30+ PTCL cohort, that's the bigger market. Salvage cHL market is small but enough to get the company to self funding.